AstraZeneca and Merck Seeking Lynparza Approval in Japan for Certain Breast Cancer Patients

AstraZeneca and Merck Seeking Lynparza Approval in Japan for Certain Breast Cancer Patients
AstraZeneca and Merck submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking the approval of Lynparza (olaparib) tablets for the treatment of patients with unresectable or recurrent BRCA-mutated breast cancer. A decision by the agency is expected by the end of 2018. This is the second new drug application for Lynparza

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *